Dannielle Appelhans - 31 Aug 2021 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role
Chief Operating Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Aug 2021
Net transactions value
$0
Form type
4
Filing time
01 Sep 2021, 20:12:45 UTC
Previous filing
16 Aug 2021
Next filing
01 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 31 Aug 2021 Common Stock 150,000 $21.72 Direct F1
transaction RUBY Restricted Stock Units Award $0 +50,000 $0.000000 50,000 31 Aug 2021 Common Stock 50,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on August 9, 2022, then in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The shares underlying the restricted stock units will vest in four equal annual installments beginning on August 9, 2022.